AMAERO
ADDITIVE MANUFACTURING
ASX:3DA

ASX Release **8 October 2020**

Upcoming Release of Shares from Escrow

Amaero International Limited ("**Amaero**") (ASX:3DA), wishes to advise that, in accordance with ASX Listing Rule 3.10A, 3,333,334 fully paid ordinary shares **("Escrowed Shares")** will be released from mandatory escrow on 15 October 2020.

The Escrowed Shares are held by the University of Adelaide and were issued under a share subscription agreement entered into by the parties on 14 October 2019. The Escrowed Shares represent 1.894% of all shares on issue.

Amaero will apply for quotation for the Escrowed Shares upon their release from escrow in accordance with the ASX Listing Rules.

This ASX release is approved by the Board of Amaero International Limited.

David Hanna
Chairman Amaero
International Limited

For Further Information, please contact:

Barrie Finnin
CEO
Amaero International Limited
info@amaero.com.au

Jane Morgan
Investor and Media Relations
+61 (0) 405 555 618
jm@janemorganmanagement.com.au

Zack McLennan
Defence Industry Media
+ 61 (0) 434 996 461
zmclennan@lunik.com.au

About Amaero International Limited:

Amaero International Limited is an Australian-based company that manufactures large format complex components in metal with laser-based additive manufacturing processes, commonly known as 3D printing.

The principal activity of Amaero is the provision of end to end additive manufacturing solutions in terms of services, equipment and technology to its key clients in the Aviation Defence and Space sectors and the Tool and Die industry.

Amaero has worked with many of the world's leading manufacturers of aerospace and defence products in both an R&D and manufacturing capability and has a demonstrated ability to deliver aviation and military specification 3D printed alloy critical operation components.

Amaero was established with the support of Monash University in 2013 to take advantage of commercial opportunities identified by the Monash Centre for Additive Manufacturing (MCAM). Amaero is co-located with MCAM in Melbourne Australia. It operates two additional facilities, in Adelaide, South Australia, and El Segundo, California, USA.